Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Addition of Rifampin to Conventional Therapy for Recurrent Furunculosis

Addition of Rifampin to Conventional Therapy for Recurrent Furunculosis Abstract REPORT OF A CASE A 33-year-old man presented to the University of Connecticut Health Center, Farmington, because of recurrent ''boils'' on his face. During the prior 5 years, Staphylococcus aureus, susceptible to cloxacillin and cephalexin, was recovered from the boils. He received multiple courses of oral antibiotics, but facial ''boils'' continued to develop, both while receiving and not receiving therapy. When first seen, the patient had two facial furuncles. Treatment with cloxacillin (250 mg four times daily), topical chlorhexidine washes, and nightly applications of intranasal mupirocin ointment was effective initially, but the lesions recurred while he was still receiving this therapy. The oral antibiotic was changed to cephalexin (500 mg twice daily). Despite this therapy, new facial furuncles developed over the next several months. THERAPEUTIC CHALLENGE Treatment of persistent or recurrent furunculosis caused by S aureus. SOLUTION Cephalexin therapy (500 mg twice daily) was continued, and rifampin therapy (300 mg References 1. Tulloch LG, Alder VG, Gillespie WA. Treatment of chronic furunculosis . BMJ. 1960;2:354-356.Crossref 2. Copeman PWM. Treatment of recurrent styes . Lancet. 1958;2:728-729.Crossref 3. Hobbs BC, Carruthers HL, Gough J. Sycosis barbae . Lancet. 1947;2:572-574.Crossref 4. Wheat LJ, Kohler RB, White A. Treatment of nasal carriers of coagulasepositive staphylococci . In: Maibach H, Aly R, eds. Skin Microbiology: Relevance to Clinical Infection . New York, NY: Springer-Verlag NY Inc; 1981:50-58. 5. Wheat LJ, Kohler RB, White A. Prevention of infections of skin and skin structures . Am J Med. 1984;76:187-190.Crossref 6. Doebbeling BN, Breneman DL, Neu HC, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment . Clin Infect Dis. 1993;17:466-474.Crossref 7. Wheat LJ, Kohler RB, Luft FC, White A. Long-term studies of the effect of rifampin on nasal carriage of coagulase-positive staphylococci . Rev Infect Dis. 1983;5( (suppl) ):s459-s462.Crossref 8. Tsankov NK, Kamarasher JA. Rifampin in dermatology . Int J Dermatol. 1993; 32:401-406.Crossref 9. Kapusnik JE, Parenti F, Sande MA. The use of rifampicin in staphylococcal infections: a review . J Antimicrob Chemother. 1984;13( (suppl C) ):61-66.Crossref 10. Traczewski MM, Goldman DA, Murphy P. In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus . Antimicrob Agents Chemother. 1983;23:571-576.Crossref 11. Hoeprich PD. Prediction of antimeningococcic chemo-prophylactic efficacy . J Infect Dis. 1971;123:125-133.Crossref 12. Farr B, Mandell GL. Rifampin . Med Clin North Am. 1982;66:157-165. 13. Grosset J, Leventis S. Adverse effects of rifampin . Rev Infect Dis 1983;5( (suppl) ): 440-444.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Addition of Rifampin to Conventional Therapy for Recurrent Furunculosis

Archives of Dermatology , Volume 131 (6) – Jun 1, 1995

Loading next page...
 
/lp/american-medical-association/addition-of-rifampin-to-conventional-therapy-for-recurrent-pdFr0ZZgzO
Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1995.01690180021003
Publisher site
See Article on Publisher Site

Abstract

Abstract REPORT OF A CASE A 33-year-old man presented to the University of Connecticut Health Center, Farmington, because of recurrent ''boils'' on his face. During the prior 5 years, Staphylococcus aureus, susceptible to cloxacillin and cephalexin, was recovered from the boils. He received multiple courses of oral antibiotics, but facial ''boils'' continued to develop, both while receiving and not receiving therapy. When first seen, the patient had two facial furuncles. Treatment with cloxacillin (250 mg four times daily), topical chlorhexidine washes, and nightly applications of intranasal mupirocin ointment was effective initially, but the lesions recurred while he was still receiving this therapy. The oral antibiotic was changed to cephalexin (500 mg twice daily). Despite this therapy, new facial furuncles developed over the next several months. THERAPEUTIC CHALLENGE Treatment of persistent or recurrent furunculosis caused by S aureus. SOLUTION Cephalexin therapy (500 mg twice daily) was continued, and rifampin therapy (300 mg References 1. Tulloch LG, Alder VG, Gillespie WA. Treatment of chronic furunculosis . BMJ. 1960;2:354-356.Crossref 2. Copeman PWM. Treatment of recurrent styes . Lancet. 1958;2:728-729.Crossref 3. Hobbs BC, Carruthers HL, Gough J. Sycosis barbae . Lancet. 1947;2:572-574.Crossref 4. Wheat LJ, Kohler RB, White A. Treatment of nasal carriers of coagulasepositive staphylococci . In: Maibach H, Aly R, eds. Skin Microbiology: Relevance to Clinical Infection . New York, NY: Springer-Verlag NY Inc; 1981:50-58. 5. Wheat LJ, Kohler RB, White A. Prevention of infections of skin and skin structures . Am J Med. 1984;76:187-190.Crossref 6. Doebbeling BN, Breneman DL, Neu HC, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment . Clin Infect Dis. 1993;17:466-474.Crossref 7. Wheat LJ, Kohler RB, Luft FC, White A. Long-term studies of the effect of rifampin on nasal carriage of coagulase-positive staphylococci . Rev Infect Dis. 1983;5( (suppl) ):s459-s462.Crossref 8. Tsankov NK, Kamarasher JA. Rifampin in dermatology . Int J Dermatol. 1993; 32:401-406.Crossref 9. Kapusnik JE, Parenti F, Sande MA. The use of rifampicin in staphylococcal infections: a review . J Antimicrob Chemother. 1984;13( (suppl C) ):61-66.Crossref 10. Traczewski MM, Goldman DA, Murphy P. In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus . Antimicrob Agents Chemother. 1983;23:571-576.Crossref 11. Hoeprich PD. Prediction of antimeningococcic chemo-prophylactic efficacy . J Infect Dis. 1971;123:125-133.Crossref 12. Farr B, Mandell GL. Rifampin . Med Clin North Am. 1982;66:157-165. 13. Grosset J, Leventis S. Adverse effects of rifampin . Rev Infect Dis 1983;5( (suppl) ): 440-444.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Jun 1, 1995

References